Form 4: Acadia Pharmaceuticals Director Equity Update

Director Edmund Harrigan acquired 8,107 shares of Acadia Pharmaceuticals common stock through the vesting of restricted stock units.

Summary

• Director Edmund Harrigan exercised and settled 8,107 restricted stock units (RSUs) into common stock on May 29, 2026.
• Following the transaction, the director holds 43,148 shares of common stock.
• The director was granted 16,004 stock options with an exercise price of $21.66, expiring May 28, 2036.
• The director was granted 9,311 additional restricted stock units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation and equity alignment.

Positives

• Director maintains a significant equity stake of 43,148 shares, aligning interests with shareholders.

Negatives

• None identified.

Risks

• Future value of equity grants is subject to market volatility and company performance.

Future Outlook

The director's new equity grants are subject to standard vesting schedules, with options vesting quarterly over one year and RSUs vesting on the earlier of one year or the next annual meeting.

Industry Context

StockSavvy.ai notes that routine equity grants to board members are standard corporate governance practices in the biotechnology sector to ensure long-term alignment with shareholder value.

Comparison to Industry Standards

• The equity compensation structure is consistent with standard practices for non-employee directors in mid-cap pharmaceutical companies.

Stakeholder Impact

• Shareholders may view the continued equity-based compensation of directors as a positive sign of long-term commitment.

Next Steps

• Vesting of 16,004 stock options quarterly over the next year.
• Vesting of 9,311 restricted stock units on the earlier of one year or the next annual meeting.

Key Dates

Keywords

Acadia Pharmaceuticals, ACAD, Insider Trading, Form 4, Equity Compensation, Director Ownership